180 Life Sciences IPO év
Mi az 180 Life Sciences IPO év?
A IPO év az 180 Life Sciences Corp. - 2020
Mi a IPO év meghatározása?
A kezdeti nyilvános ajánlattétel olyan nyilvános ajánlattétel, amelyben a társaság részvényeit általában olyan intézményi befektetőknek adják el, akik viszont értékpapírcserében először értékesítik a nagyközönségnek.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO év a Health Care szektor a NASDAQ-on cégekben a 180 Life Sciences -hoz képest
Mit csinál 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
ipo év -hoz hasonló cégek 180 Life Sciences
- Acusensus Ltd nak IPO év 2019 van
- Grayscale Ethereum Trust (ETH) nak IPO év 2019 van
- Powerwrap Ltd nak IPO év 2019 van
- Powerwrap nak IPO év 2019 van
- National Rural Utilities Cooper nak IPO év 2019 van
- Listed Funds Trust nak IPO év 2019 van
- 180 Life Sciences nak IPO év 2020 van
- Globally Local Technologies nak IPO év 2021 van
- uniQure N.V nak IPO év 2021 van
- Trustpilot plc nak IPO év 2021 van
- IQVIA nak IPO év 2021 van
- ACTIA S.A nak IPO év 2021 van
- Remark nak IPO év 2021 van